<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612950</url>
  </required_header>
  <id_info>
    <org_study_id>KA 03005</org_study_id>
    <secondary_id>KA 03005</secondary_id>
    <nct_id>NCT00612950</nct_id>
  </id_info>
  <brief_title>Beta-Cell Function After Near-Normalisation of Blood Glucose</brief_title>
  <official_title>Four Weeks of Near Normalisation of Blood Glucose Improves the Insulin Response to GLP-1 and GIP in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to
      impaired potentiation of beta-cell responsiveness to glucose by glucose dependent
      insulinotropic polypeptide and glucagon-like peptide-1 respectively. The aim of the present
      study was to investigate whether 4 weeks of near-normalization of blood glucose could improve
      the insulin responses to GIP and GLP-1 in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2.phase insulin response measured as incremental area under the curve from 10-120 minutes</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucagon-like peptide-1,</intervention_name>
    <description>GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.</description>
    <arm_group_label>GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose dependent insulinotropic polypeptide</intervention_name>
    <description>continuous infusion of GIP (1½ pmol/kg/min) for 120 min.</description>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>continuous infusion of Saline for 120 min</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years

          -  Type 2 diabetes diagnosed after 30 years of age

          -  BMI &gt; 25

        Exclusion Criteria:

          -  Severe complications to diabetes

          -  Abnormal liver and kidney function

          -  Haemoglobin below the lower limit

          -  Macroalbuminuria

          -  Systemic disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia V Højberg, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hvidovre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Endocrinology, Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <last_update_submitted>February 11, 2008</last_update_submitted>
  <last_update_submitted_qc>February 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Patricia Verdugo Højberg/ MD, PHD</name_title>
    <organization>Kettegaard Alle 30, 2650 Hvidovre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

